A Trial Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin FlexPro) in Growth Hormone Treatment naive Pre-pubertal Children With Growth Hormone Deficiency naive Pre-pubertal Children With Growth Hormone Deficiency
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Nov 2017
At a glance
- Drugs Somapacitan (Primary) ; Somatropin
- Indications Somatotropin deficiency
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 20 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Sep 2017 Planned End Date changed from 2 Oct 2020 to 31 Aug 2020.
- 03 May 2017 Planned End Date changed from 17 Apr 2020 to 2 Oct 2020.